Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

X
Trial Profile

A Phase 3b Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary) ; Apremilast
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMpulse
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Mar 2024 Results comparing efficacy in skin clearance (sPGA0/1, PASI90, PASI75, PASI100) in patients with baseline nail or scalp psoriasis at week-16, presented at the American Academy of Dermatology annual Meeting 2024
    • 12 Mar 2024 Results Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life presented at the American Academy of Dermatology annual Meeting 2024
    • 06 Mar 2024 According to AbbVie media release, data from the study will be presented during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top